对EGFR-TKIs在高级非小细胞肺癌的症状和死亡率的有效性,白天与夜间的治疗
Onam Ok1, Mangyeong Lee2,3, Nayeon Kim1,2,4
1Department of Nursing, Graduate School of Clinical Nursing Science, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.
概括
晚上服用EGFR-TKIs可以减少副作用,并改善转移性肺癌患者的存活率. 这种时间策略可能会提高肺癌治疗的治疗结果.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 转移性肺癌需要有效的向治疗.
- 表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 在治疗特定的肺癌中至关重要.
- 优化口服EGFR-TKIs的服用时间表可能会改善患者的治疗结果.
研究的目的:
- 调查日间和夜间对EGFR-TKI的服用对副作用的影响.
- 评估EGFR-TKI计时对转移性肺癌患者全因死亡率的影响.
主要方法:
- 一项前性队列研究与87名新诊断的转移性肺癌患者进行.
- 暴露被定义为白天和夜间摄入口服EGFR-TKI (gefitinib,erlotinib,afatinib) 的暴露.
- 通过移动应用程序监测症状变化,并在平均43个月内追踪所有原因的死亡率.
主要成果:
- 与白天使用相比,夜间使用EGFR-TKI与皮肤相关的副作用 (,皮肤干燥) 显著减少.
- 晚上服用EGFR-TKIs的患者报告说,肺癌相关症状的减少更大.
- 夜间组的全因死亡风险较低,特别是在年轻的患者中.
结论:
- 晚上服用EGFR-TKIs可能会减轻副作用,并改善转移性肺癌的整体存活率.
- 临床医生应考虑每天服用一次口服抗癌药物的晚上用量,以提高治疗效率和患者的生活质量.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...